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Background: Long non-coding RNAs play an important role in tumorigenesis, hence, identification of cancer-
associated lncRNAs and investigation of their biological functions and molecular mechanisms are important for
understanding the development and progression of cancer. Recently, the downregulation of lncRNA MEG3 has
been observed in various human cancers. However, its role in non-small cell lung cancer (NSCLC) is unknown. The
aim of this study was to examine the expression pattern of MEG3 in NSCLC and to evaluate its biological role and
clinical significance in tumor progression.
Methods: Expression of MEG3 was analyzed in 44 NSCLC tissues and 7 NSCLC cell lines by qRT-PCR. Over-
expression approaches were used to investigate the biological functions of MEG3 in NSCLC cells. Bisulfite
sequencing was used to investigate DNA methylation on MEG3 expression. The effect of MEG3 on proliferation was
evaluated by MTT and colony formation assays, and cell apoptosis was evaluated by Hoechst staining and
Flow-cytometric analysis. NSCLC cells transfected with pCDNA-MEG3 were injection into nude mice to study the
effect of MEG3 on tumorigenesis in vivo . Protein levels of MEG3 targets were determined by western blot analysis.
Differences between groups were tested for significance using Student’s t-test (two-tailed).
Results: MEG3 expression was decreased in non-small cell lung cancer (NSCLC) tumor tissues compared with
normal tissues, and associated with advanced pathologic stage, and tumor size. Moreover, patients with lower
levels of MEG3 expression had a relatively poor prognosis. Overexpression of MEG3 decreased NSCLC cells
proliferation and induced apoptosis in vitro and impeded tumorigenesis in vivo. MDM2 and p53 protein levels were
affected by MEG3 over-expression in vitro.
Conclusions: Our findings indicate that MEG3 is significantly down-regulated in NSCLC tissues that could be
affected by DNA methylation, and regulates NSCLC cell proliferation and apoptosis, partially via the activition of
p53. Thus, MEG3 may represent a new marker of poor prognosis and is a potential therapeutic target for NSCLC
intervention.
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Non-small cell lung cancer (NSCLC) including adeno-
carcinoma and squamous cell carcinoma, is a predomin-
ant form of lung cancer, and accounts for the majority
of lung cancer associated deaths worldwide [1]. Despite
the recent advances in clinical and experimental oncol-
ogy, the prognosis of lung cancer is still unfavorable,
with a 5-year overall survival rate of approximately 11%
[2]. Thus, a detailed understanding of the mechanisms
underlying NSCLC development and progression is
essential for improving diagnosis, prevention and treat-
ment of this disease. Recently, there is growing evidence
indicating that non-coding RNAs may be involved in
NSCLC pathogenesis, providing new insights into the
biology of this disease [3,4].
Recent improvements in high-throughput transcrip-
tome analysis in the last few years, have led to the
discovery that > 90% of the total mammalian genome
can be transcribed and may yield many short or long non-
coding RNAs (lncRNAs) with limited or no protein-coding
capacity [5,6]. Although many studies have helped unravel-
ing the function of microRNAs, the lncRNAs counterpart
of the transcriptome is less well characterized. lncRNAs
are known to play important roles during cellular develop-
ment and differentiation, and a large range of functions,
such as modulation of proliferation and invasiveness of tu-
mors [7], and reprogramming of induced pluripotent stem
cells [8] have been attributed to lncRNAs. Dysregulation of
some lncRNAs has been shown in various types of cancers,
such as breast cancer, hepatocellular carcinoma, melan-
oma, bladder cancer, and prostate cancer [7,9-14]. One
such lncRNA, HOTAIR, has been determined as a negative
prognostic indicator in breast, liver and pancreatic cancer
patient survival, evidencing a close association with breast
cancer cell metastasis [7,15,16]. Recent studies have also
revealed the contribution of lncRNAs, as proto-oncogenes
(e.g. ANRIL) and tumor suppressor genes (e.g. MEG3) in
tumorigenesis [17,18].
Maternally expressed gene 3 (MEG3), an lncRNA, is
expressed in many normal tissues. However, MEG3 expres-
sion is lost in an expanding list of primary human tumors,
and promoter hypermethylation or hypermethylation of
the intergenic differentially methylated region has been
shown to contribute to the loss of MEG3 expression in
tumors [19,20]. MEG3 represents as a tumor suppressor
gene, and its ectopic expression can inhibit cell prolifera-
tion and promote cell apoptosis in human glioma cell lines
[21]. Moreover, accumulation of p53 (TP53) protein and
its target gene expression partly contribute to cell growth
inhibition induced by MEG3 [22]. However, very little is
known about MEG3 expression level in NSCLC, and its
role in NSCLC development.
In this study, we demonstrated that MEG3 expression
was significantly decreased in NSCLC tissues comparedto adjacent normal tissues. The correlation between
MEG3 downregulation and advanced pathologic stage,
tumor size, and patient survival time was also explored.
Moreover, ectopic expression of MEG3 inhibited cell
proliferation and promoted cell apoptosis in human
NSCLC cell lines and overexpression of MEG3 was able
to impede the development of tumors in vivo. We fur-
ther verified that overexpression of MEG3 could induce
the activation of p53. Taken together, this study indi-
cated that lncRNA, especially MEG3 plays an important
role in NSCLC development and could be a potential
therapeutic target for patients with NSCLC.
Methods
Patient and tissue samples
Paired NSCLC and adjacent non-tumor lung tissues
were obtained from 44 patients who underwent primary
surgical resection of NSCLC between 2006 and 2007 at
First Affiliated Hospital of Nanjing Medical University,
China. NSCLC and normal tissues were immediately
snap-frozen in liquid nitrogen and stored at −80°C until
total RNA was extracted. Tumor samples were at least
80% composed of viable-appearing tumor cells on histo-
logical assessment. The pathological stage, grade and
nodal status were appraised by an experienced patholo-
gist. Clinicopathologic characteristics including tumor-
node-metastasis (TNM) staging were also collected. The
study was approved by the Research Ethics Committee
of Nanjing Medical University, China. Informed written
consents were obtained from all patients who partici-
pated in this study.
Cell lines and culture conditions
Six NSCLC adenocarcinoma cell lines (A549, SPC-A1,
NCI-H1650, NCI-H358, NCI-H1299, NCI-H1975), a
NSCLC squamous carcinomas cell line (SK-MES-1),
and a normal human bronchial epithelial cell line
(16HBE) were purchased from the Institute of Biochem-
istry and Cell Biology of the Chinese Academy of
Sciences (Shanghai, China). 16HBE, A549, NCI-H1650,
NCI-H358, NCI-H1975 and NCI-H1299 cells were cul-
tured in RPMI 1640 medium; SPC-A1, and SK-MES-1
cells were cultured in DMEM (GIBCO-BRL) medium,
supplemented with 10% fetal bovine serum (10% FBS),
100 U/ml penicillin, and 100 mg/ml streptomycin
(Invitrogen, Shanghai, China) in humidified air at 37°C
with 5% CO2.
RNA extraction and qRT-PCR analysis
Total RNA was isolated with TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
protocol. 500 ng total RNA was reverse transcribed in a
final volume of 10 μl using random primers under stand-
ard conditions using the PrimeScript RT reagent Kit.
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the PrimeScript RT reagent Kit and SYBR Premix Ex Taq
(TaKaRa, Dalian, China) according to the manufacturer’s
instructions.
The relative levels of MEG3 were determined by qPCR
using gene specific primers. GAPDH was measured as
an internal control, as its expression showed minimal vari-
ation in different cell lines and cancer specimens. The RT
reaction was carried out under the following conditions:
37°C for 15 min; 85°C for 5 sec; and then held on 4°C.
After the RT reaction, 1ul of the complementary DNA
was used for subsequent qRT-PCR reactions. The PCR
primers for MEG3 or GAPDH were as follows: MEG3
sense, 5′ CTGCCCATCTACACCTCACG 3′ and reverse,
5′ CTCTCCGCCGTCTGCGCTAGGGGCT 3′; GAPDH
sense, 5′ GTCAACGGATTTGGTCT GTATT 3′ and re-
verse, 5′ AGTCTTCTGGGTGGCAGTGAT 3′. The PCR
reaction was conducted at 95°C for 30 s and followed by
40 cycles of 95°C for 5 s and 60°C for 34 s in the ABI 7500
real-time PCR system (Applied Biosystems, Foster City,
CA, USA). The qPCR results were analyzed and expressed
as relative mRNA expression of CT (threshold cycle)
value, which was then converted to fold changes.
Methylation analysis of CpG island
For determination of methylation status of the CpG island,
genomic DNA prepared from NSCLC cells and normal
tissues, was modified by sodium bisulfite (EZ DNA
Methylation Kit , Zymo Research), followed by PCR using
the sense primer 5′ TTTTTTTGTTGTAATTTGGGTG
3′ and reverse, 5′ ACGAATACCGTCTTCCTTTTAC 3′,
respectively. PCR-amplified product was transformed in E.
coli DH5α cells. Subsequently obtained plasmids were
subjected to sequencing.
Treatment of SPC-A1 cells with 5-aza-2-deoxy-cytidine
(5-aza-CdR)
SPC-A1 cells (2.5 × 105) were seeded into six-well culture
plate on day 0 and exposed to 0, 2 or 5 μM 5-aza-CdR
(Sigma-Aldrich, USA)from day 1 to day 3. The cells
treated with 5-aza-CdR were harvested on day 3 and
used for detection of MEG3 expression.
Plasmid constructs
The sequence of MEG3 was synthesized and subcloned
into pCDNA3.1 (Invitrogen, Shanghai, China). Ectopic
expression of MEG3 was achieved by using the pCDNA-
MEG3 transfection and empty pCDNA vector (empty)
was used as control. The expression level of MEG3 was
detected by qPCR.
Transfection of NCSCL cells
All plasmid vectors (pCDNA-MEG3 and empty vector)
for transfection were extracted by DNA Midiprep orMidiprep kit (Qiagen, Hilden, Germany). SPC-A1 and
A549 cells cultured on six-well plate were transfected
with the pCDNA -MEG3 or empty vector using Lipo-
fectamine2000 (Invitrogen, Shanghai, China) according
to the manufacturer’s instructions. Cells were harvested
after 48 hours for qRT-PCR and western blot analyses.
Cell proliferation assays
Cell proliferation was monitored using Cell Proliferation
Reagent Kit I (MTT) (Roche Applied Science). pCDNA-
MEG3 and empty vector transfected SPC-A1 cells (3000/
well) were allowed to grow in 96-well plates. Cell prolifer-
ation was measured every 24 hours following the manu-
facturer’s protocol. All experiments were performed in
quadruplicate. For colony formation assay, a total of 500
pCDNA-MEG3 and empty vector cells were placed in a
fresh six-well plate and maintained in media containing
10% FBS, replacing the medium every 4 days. After
14 days, cells were fixed with methanol and stained with
0.1% crystal violet (Sigma-Aldrich (country???)). Visible
colonies were manually counted. Triplicate wells were
measured for each treatment group.
Flow-cytometric analysis of apoptosis
SPC-A1 and A549cells transfected with pCDNA-MEG3
and empty vector were harvested 48 hours after trans-
fection by trypsinization. Following double staining with
FITC-Annexin V and Propidium iodide (PI), the cells
were analyzed using flow cytometry (FACScan®; BD
Biosciences) equipped with a CellQuest software (BD
Biosciences) [23]. Cells were discriminated into viable
cells, dead cells, early apoptotic cells, and apoptotic cells.
The percentage of early apoptotic cells were compared
to control groups from each experiment. All of the sam-
ples assayed were in triplicates.
Hoechst staining assay
SPC-A1 and A549 cells transfected with pCDNA-MEG3
and empty vector were cultured in six-well plates, and
were incubated with Hoechst 33342 solution (50 ng/ml,
Sigma-Aldrich, St Louis, MO, USA) for 10 min at room
temperature. Cells were then washed twice with PBS and
changes in nuclear morphology were detected by fluores-
cence microscopy using 365 nm filter for Hoechst 33342.
For quantification of Hoechst 33342 staining, the percent-
age of Hoechst -positive nuclei per optical field (at least 50
fields) was counted in three independent experiments.
Tumor formation assay in a nude mouse model
Female athymic BALB/c nude mice aged 4 weeks were
maintained under specific pathogen-free conditions and
manipulated according to protocols approved by the
Shanghai Medical Experimental Animal Care Commis-
sion. SPC-A1 cells were transfected with pCDNA-MEG3
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culture plates, washed with PBS, and resuspended at a
concentration of 2 × 107 cells/mL. A volume of 0.1 mL
of suspended cells was subcutaneously injected into a
single side of the posterior flank of each mouse. Tumor
growth was examined every three days, and tumor
volumes were calculated using the equation V = 0.5 ×
D × d2 (V, volume; D, longitudinal diameter; d, latitu-
dinal diameter) [16]. At 3 weeks post injection, mice
were euthanized, and the subcutaneous growth of each
tumor was examined.
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
The protocol was approved by the Committee on the
Ethics of Animal Experiments of the Nanjing medical
University (Permit Number: 200933). All surgery was
performed under sodium pentobarbital anesthesia, and all
efforts were made to minimize suffering in mice [24].
Western blotting assay
Cells were lysed using mammalian protein extraction re-
agent RIPA (Beyotime china) supplemented with prote-
ase inhibitors cocktail (Roche. Switzerland) and PMSF
(Roche, Switzerland). Protein concentration was mea-
sured with the Bio-Rad protein assay kit. 50 μg protein
extractions were separated by 12% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE), then transferred to 0.22 μm
nitrocellulose membranes (Sigma-Aldrich. USA)and incu-
bated with specific antibodies. ECL chromogenic substrate
was used to visualize the bands and the intensity of the
bands was quantified by densitometry (Quantity One soft-
ware; Bio-Rad). GAPDH was used as control. GAPDH
antibody was purchased from sigma-Aldrich (USA), P53
antibody was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA), P21 antibody was purchased from
Cell Signaling Technology (MA, USA).
Statistical Analysis
Student’s t-test (two-tailed), One-way ANOVA and
Mann–Whitney test were performed to analyze the data
using SPSS 16.0 software. P values less than 0.05 were
considered statistically significant.
Results
MEG3 expression is downregulated in human NSCLC
tissues
qRT–PCR analysis was used to measure MEG3 expression
in 44 NSCLC tissues and normal counterparts. The expres-
sion of MEG3 was significantly downregulated in NSCLC
tissues (Figure 1A). Furthermore, correlation analysis of
MEG3 expression with clinical pathological features of
NSCLC patients, revealed a significant association between
MEG3 downregulation and advanced pathological stage (I/II,37; IIIa/b,IV,7) and NSCLC tumor size (Figure 1B,C).
However, MEG3 expression was not correlated with histo-
logical subtype, patient age, gender, or tumor position
(Figure 1D and Table 1). Clinical data of individual
patients is shown in Additional file 1: Table S1.
Kaplan-Meier survival analysis and log-rank tests using
patient postoperative survival were performed to further
evaluate the correlation between MEG3 expression and
NSCLC patient prognosis. According to the median ratio
of relative MEG3 expression (0.27) in tumor tissues, the
44 NSCLC patients were classified into two groups:
High-MEG3 group (n = 21, MEG3 expression ratio ≥
mean ratio) and Low-MEG3 group (n = 21, MEG3 expres-
sion ratio ≤mean ratio). The Kaplan-Meier survival curve
showed that patients with decreased MEG3 expression
levels had significantly shorter survival times than those
with high MEG3 expression levels (Figure 1D). These
findings support the hypothesis that decreased MEG3
expression plays a key role in NSCLC development and
progression.
Effect of DNA methylation on MEG3 expression
We next performed qRT-PCR analysis to examine the
expression of MEG3 in 7 human NSCLC cell lines,
including both adenocarcinoma and squamous carcin-
oma subtypes. Of these, five cell lines (A549, SPC-A1,
NCI-H1650, NCI-H1975 and SK-MES-1) expressed
lower levels of MEG3 compared with the normal bron-
chial epithelial cell line and 16HBE, while NCI-H358
and H1299 cells expressed relatively higher endogenous
levels of MEG3 (Figure 2A). The expression of lncRNA
is more cell sepecific [25], which may contribute to the
different expression level of MEG3 in NSCLC cell lines.
The expression of MEG3 was frequently downregulated
in NSCLC, and hypermethylation of MEG3-MDR has
been reported to be involved in MEG3 transcriptional in-
activation. Following treatment of SPC-A1 cells with DNA
demethylating agent (5-aza-CdR), we found that MEG3
expression was significantly increased by 1.95- or 3.08-
fold in 5-aza-CdR treated cells compared with control
(Figure 2B). Moreover, among the three canonical CpG
island of MEG3-DMR loci (DMR1, DMR2 and DMR3),
we examined the methylation pattern of DMR2 in
NSCLC and normal tissues by bisulfite sequencing, and
the average frequency of methylation was 68% in normal
tissues and 96% in NSCLC tissues (Figure 2C). These
results indicate that downregulation of MEG3 observed in
NSCLC cells might have been partly due to hyper-
methylation of MEG3-DMR.
Effect of MEG3 on cell proliferation in vitro
MEG3 was overexpressed in SPC-A1 and A549 cells by
transfecting them with pCDNA-MEG3. qRT-PCR ana-
lysis of MEG3 levels revealed that MEG3 expression was
Figure 1 qRT-PCR analysis of lncRNA MEG3 in NSCLC tissues. (A) MEG3 expression in NSCLC tissues and its clinical significance. MEG3 was
measured in 44 pair NSCLC and normal tissues by qRT-PCR (shown as ΔCT). (B and C) Data are presented as relative expression level in tumor tissues
(shown as ΔCT). MEG3 expression was significantly lower in patients with a higher pathological stage and big tumor size. (D) Patients with low levels of
MEG3 expression showed reduced survival times compared to patients with high levels of MEG3 expression (log rank P < 0.001). **, P < 0.01.
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respectively following transfection with pCDNA-MEG3
compared with control (Figure 3A).
To assess the biological role of MEG3 in NSCLC, we
investigated the effects of targeted overexpression of
MEG3 on cell proliferation. MTT assay revealed that cell
growth was significantly impaired in SPC-A1 and A549
cells transfected with pCDNA-MEG3 compared with
controls (Figure 3B). Similarly, the results of colony-
formation assays revealed that clonogenic survival was
decreased following enhanced MEG3 expression in SPC-
A1 and A549 cells (Figure 3C). To further examinewhether the effect of MEG3 on proliferation of NSCLC
cells was on cell cycle regulation, cell cycle progression
was analyzed by flow cytometry. The results revealed
that SPC-A1 and A549 cells transfected with pCDNA-
MEG3 had an obvious cell cycle arrest at the G1/G0
phase and had a decreased G2/S phase (Figure 3D).
Moreover, inhibition of MEG3 expression in H1299 cells
promoted cells proliferation (Additional file 2: Figure S1)
Effect of MEG3 on cell apoptosis and invasion
To determine whether apoptosis was a contributing
factor to cell growth inhibition, we performed Hochest
Figure 2 Analysis of the correlation between methylation status and
cell lines (A549, SPC-A1, NCI-H1650, NCI-H1299, NCI-358, NCI-H1975 and SK
(16HBE) by qRT-PCR. (B) The level of MEG3 expression in SPC-A1 cells follow
the CpG island of MEG3 was assessed by bisulfite sequencing in NSCLC and
methylated CpG sites, respectively. Each row represents a single clone. *P <




n (%) Relative expression
of MEG3a
P-valueb
Gender P = 0.653
Male 34 (77) 0.36
Female 10 (23) 0.42
Site of tumor P = 0.758
Left lung 19 (43) 0.31
Right lung 25 (57) 0.39
Differentiation P = 0.073
Poor 16 (36) 0.27
Moderate 28 (64) 0.45
Lymph node metastasis P = 0.042
Yes 27 (61) 0.42
No 17 (39) 0.64
Correlation of the expression of MEG3 with clinicopathologic features. a
Median of relative expression. b P < 0.05 was considered significant
(Mann–Whitney U test between 2 groups and Kruskall-Wallis test for 3 groups).
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with pCDNA-MEG3. The apoptotic rate of SPC-A1 and
A549 cells transfected with pCDNA-MEG3 increased by
approximately 11% and 12% respectively in comparison
with cells transfected with empty vector (Figure 4A,B).
Cell invasion is a significant aspect of cancer progres-
sion, and involves the migration of tumor cells into
contiguous tissues and the dissolution of extracellular
matrix proteins. To investigate whether MEG3 had a dir-
ect functional role in facilitating cell invasion in NSCLC,
we evaluated cancer cell invasion through transwell
matrigel assay. However, alteration of MEG3 expression
had no significant effects on cell invasion compared with
control (data not shown).
MEG3 inhibits tumorigenesis of NSCLC cells in vivo
To explore whether the level of MEG3 expression af-
fects tumorigenesis, pCDNA-MEG3 and empty vector
stably-transfected SPC-A1 cells were inoculated into
female nude mice. Eighteen days after injection, theexpression of MEG3. (A) Analysis of MEG3 expression levels in NSCLC
-MES-1) compared with the normal bronchial epithelial cell line
ing 5-aza-dC (0, 5, 10 μM) treatment. (C) The methylation status of
normal tissues. Open and filled squares denote unmethylated and
0.05; **P < 0.01.
Figure 3 Effects of MEG3 on cell proliferation in vitro. (A) Analysis of MEG3 expression levels in SPC-A1 and A549 cells transfected with
PCDNA-MEG3 or empty vector by qRT-PCR. (B) MTT assay was performed to determine the proliferation of SPC-A1 and A549 cells. Data represent
the mean ± S.D. from three independent experiments. (C) Colony-forming growth assays were performed to determine the proliferation of
SPC-A1 and A549 cells. The colonies were counted and captured. (D) The bar chart represented the percentage of cells in G0/G1, S, or G2/M
phase, as indicated. All experiments were performed in biological triplicates with three technical replicates.*P < 0.05, **P < 0.01.
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tially smaller than those in the empty vector group
(Figure 5A). Moreover, the mean tumor weight at the end
of the experiment was markedly lower in the pCDNA-
MEG3 group (0.35 ± 0.11 g) compared to the control
group (0.81 ±0.15 g) (Figure 5B). qRT-PCR analysis of
MEG3 expression was then performed in selected tumor
tissues. The results showed that the levels of MEG3
expression in tumor tissues formed from pCDNA-MEG3
cells were higher than those of tumors formed in control
group (Figure 5C). Immunostaining was used to analyze
PCNA protein expression in resected tumor tissues.
PCNA levels in tumors formed from control cells (empty
vector), exhibited decreased positivity for PCNA than in
tumors from pCDNA-MEG3 transfected SPC-A1 cells
(Figure 5D). These results indicate that overexpression of
MEG3 could inhibit tumor growth in vivo.
MEG3 stimulates activation of p53 protein
Further exploration of the mechanisms involved in
MEG3 overexpression induced growth arrest and apop-
tosis was done by examining the expression of p53
protein after transfection with pCDNA-MEG3 or empty
vector. Recent studies have indicated that lncRNAs may
play an important role in the regulation of cell growth
by modulating p53 pathway [26]. The results of western
blot analysis showed that the expression of p53 wassignificantly increased and the expression of MDM2
was downregulated in SPC-A1 cells transfected with
pCDNA-MEG3 compared to those with empty vector.
No significant differences were observed in the expres-
sion levels of p21 in SPC-A1 cells transfected with
pCDNA-MEG3 compared to those with empty vector
(Figure 6). These data confirm that MEG3 functions as
a tumor suppressor gene by regulating p53 activation in
NSCLC.
Discussion
Recently, genome-wide surveys have revealed that the
human genome contains ~20000 protein-coding genes
and >98% of the total genome can be transcribed, yield-
ing many short or long noncoding RNAs (lncRNAs)
with limited or no protein-coding capacity [27,28]. There
are over 3000 human lncRNAs greater than 200nt in
length, but less than 1% of them have been characterized
[5,29]. Although only a minority have been characterized
in detail, recent studies showed that lncRNAs participates
in diverse biological processes including cell cycle control
and cell differentiation through distinct mechanisms, such
as imprinting, chromosome dosage-compensation, epigen-
etic regulation, mRNA splicing, nuclear and cytoplasmic
trafficking [30-32]. Several studies have further demon-
strated that lncRNAs are efficiently regulated during devel-
opment in response to diverse signaling, and dysregulation
Figure 4 Effects of MEG3 on cell apoptosis. (A) Hoechst staining assay for cell apoptosis; the percentage of Hoechst-positive nuclei per optical
field (at least 50 fields) was counted. (B) The apoptotic rates of cells were detected by flow cytometry. *P < 0.05 and **P < 0.01.
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provide a cellular growth advantage, resulting in progres-
sive and uncontrolled tumor growth [10,16,33,34]. Al-
though lncRNAs may have impact on human cancers, the
basis of their molecular mechanisms is still not well
known. Therefore, the interplay between proteins and
lncRNAs is an important topic in the field of cancer
biology, in which lncRNAs may provide the missing clue of
the well-known oncogenic and tumor suppressor network.
To date, many lncRNAs have been identified, and their
involvement in human cancer has been extensively
reported. The lncRNA MALAT-1 expression was markedly
increased in primary bladder tumors that subsequently
showed evidence of metastasis, and its overexpression
could promote bladder cancer cells invasion by modulating
epithelial-mesenchymal transition (EMT)-associated ZEB1,
ZEB2, Slug and E-cadherin levels or by activating Wnt
signaling [35]. In this study, we found that the expression
of lncRNA MEG3 was decreased in NSCLC tissues when
compared to normal tissues. Specifically, MEG3 expression
was found to be significantly lower at later stages of tumor
development and in tumors that had undergone increase
in size. Moreover, the overall survival time of patients with
moderate or strong MEG3 expression levels was signifi-
cantly higher than that of patients with lower MEG3
expression levels. Moreover, loss or significant reduction ofMEG3 expression in various human primary tumors
including neuroblastomas, hepatocellular cancers and
gliomas has been well documented [21,36,37]. In addition,
we demonstrate that MEG3 expression is lost in multiple
NSCLC cell lines compared to a normal human bronchial
epithelial cell line (16HBE). Similarly, loss ofMEG3 expres-
sion has also been found in many cancer cell lines includ-
ing those derived from brain, bladder, bone marrow,
breast, cervix, colon, liver, lung, meninges and prostate
[18]. We also showed that DNA methylation may underlie
the lost expression of MEG3 in NSCLC tissues. This sug-
gests that the decreased expression ofMEG3 may be medi-
ated by DNA methylation and useful in the development
of novel prognostic or progression markers for NSCLC.
In order to highlight the impact of dysregulated
expression and function of MEG3, we show the critical
role of MEG3 in the development of NSCLC. Ectopic
expression of MEG3 by transfection decreased the cell
growth, and led to the promotion of cell apoptosis in vitro
and in vivo. To further investigate how MEG3 induces
NSLCC cells apoposis and growth arrest, we examined the
level of p53 after transfection of pCDNA-MEG3 in SPC-
A1 cells. We found that re-expression of MEG3 could
significantly stimulate the level of p53 protein. Peng-jun
Wang and Yunli Zhou have also reported that non-coding
RNA MEG3 may function as a tumor suppressor mediated
Figure 5 Effects of MEG3 on tumor growth in vivo. (A) The tumor volume was calculated once every three days after injection of SPC-A1 cells
stably transfected with PCDNA-MEG3 or empty vector. Points, mean (n = 3); bars indicate S.D. (B) Tumor weights are represented as means of
tumor weights ± s.d. (C) QPCR analysis of MEG3 expression in tumor tissues formed from SPC-A1/MEG3, SPC-A1/NC. (D). Tumors developed from
PCDNA-MEG3 transfected SPC-A1 cells showed lower PCNA protein levels than tumors developed by control cells. Upper: H & E staining; Lower:
immunostaining. *P < 0.05, **P < 0.01 and N.S. not significant.
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transcription factor, p53 is capable of regulating expression
of many target genes leading to the suppression of tumor
development and growth, and it is mutated in most human
cancers [38]. Generally, p53 level is very low due to rapidFigure 6 MEG3 increased p53 activation. Western blot analysis of p53
transfection. Results shown are from 3 independent experiments. GAPDHdegradation via the ubiquitin-proteasome pathway. The
ubiquitination of p53 is mainly mediated by MDM2, an E3
ubiquitin ligase. Inhibition of MDM2 plays a major role in
p53 stabilization. A decrease in MDM2 protein level was
observed in SPC-A1 cells transfected with pCDNA-MEG3,, MDM2 and p21 after pCDNA-MEG3 or empty vector
protein was used as an internal control. * P < 0.05; ** P < 0.01.
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mechanisms by which MEG3 activates p53. Interestingly,
the results revealed that MEG3 does not stimulate p21Cip1
expression, a well-known p53 target gene. These findings
indicate that lncRNA MEG3 may function as a tumor
suppressor by activating p53 and underlying target genes,
but not p21Cip1, and its deficiency or decreased expression
or function could contribute to NSCLC development.
Conclusions
In summary, we demonstrate that the loss of lncRNA
MEG3 expression is a common event underlying
NSCLC, suggesting that MEG3 may play a key func-
tional role in NSCLC developmeng and as a negative
prognostic factor for NSCLC patients and an indicative
of poor survival rates. The current study provides novel
role of lncRNAs, specifically MEG3, and may help us to
better understand the pathogenesis and development of
NSCLC. Further understanding of this mechanism will
foster the development of lncRNA-directed diagnostic
and therapeutic agents against NSCLC.
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